ClinicalTrials.gg
RecruitingNCT07546383Updated Apr 22, 2026

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

An interventional study of Iparomlimab and tuvonralimab in Squamous Cell Carcinoma of Head and Neck, sponsored by The Second Affiliated Hospital of Hainan Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by The Second Affiliated Hospital of Hainan Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 172 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.

Planned enrollment
198th of 266
32 · median 66
Started
2026
with 54 others
No phase
21 of 291
14 open now
Primary completion
2027-12
later than 137 of 204 live
Registered
253rd of 291
by date

Among the 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 198th largest by planned enrollment of the 266 interventional ones that give a count, is one of 55 that started in 2026, is one of 21 with no phase, reaches primary completion later than 137 of the 204 other live ones, and was the 253rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

172 of the 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:

167 more — sign in →

All 172 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of the combination of the antibodies iparomlimab and tuvonralimab, administered with or without chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have progressed after receiving at least one line of systemic therapy.

The study includes a safety run-in phase with approximately three patients, which may be expanded to six if a dose-limiting toxicity is observed. Patients are then assigned to either combination antibody monotherapy or combination antibody plus chemotherapy, based on PD-L1 combined positive score (CPS), symptom burden, disease characteristics and patient preference.

Monotherapy involves iparomlimab and tuvonralimab (5 mg/kg on day 1, every 3 weeks).

Combination therapy involves the same antibody regimen plus up to six cycles of platinum (carboplatin at an area under the curve (AUC) of 5 or cisplatin at 75 mg/m²) plus docetaxel (75 mg/m²) or paclitaxel (135-175 mg/m²), followed by antibody monotherapy maintenance.

The primary objective is to assess the objective response rate (ORR) according to RECIST 1.1. The secondary objectives are to evaluate the disease control rate (DCR), the 6-month progression-free survival (PFS) rate, the 6-month overall survival (OS) rate and the safety profile. Exploratory objectives include the association of tumour biomarkers (PD-L1 expression and tumour mutation burden) with efficacy.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign a written form before any trial-related procedures are performed;
  2. Ages 18 to 75, regardless of gender;
  3. performance status of 0-2;
  4. confirmed recurrent or squamous cell carcinoma of the head and neck, including the oropharynx, oral cavity, hypopharynx, or larynx;
  5. Has received systemic therapy for recurrent or metastatic HNSCC;
  6. Expected survival time > 3 months;
  7. At least one according to the 1.1 criteria
  8. All acute toxicities resulting from prior anticancer therapy must have resolved to Grade 0-1 (according to Version 5.0) or to a level acceptable under the inclusion/exclusion criteria;
  9. Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within the normal range. (These levels may be controlled by thyroid replacement therapy.) Asymptomatic subjects with abnormal T3, free T3, or free T4 levels may be enrolled;
  10. Patients must have adequate organ and bone marrow function, and laboratory test results within 7 days prior to grouping must meet the following requirements (conditions must not be met by administering any blood components, cell growth factors, albumin, or other corrective medications within 14 days prior to obtaining the laboratory tests), as follows: 1) Complete blood count (CBC): (ANC) ≥ 1.5 × 10⁹/L; count (PLT) ≥ 75 × 10⁹/L (≥ 50 × 10⁹/L for patients with cirrhosis or splenomegaly); (HGB) ≥ 90 g/L; 2) Liver function: Serum total (TBIL) ≤ 1.5× (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 5×ULN; 3) Renal function: Serum creatinine (Cr) ≤ 1.5×ULN or (CCr) ≥ 50 mL/min (Cockcroft-Gault formula); Qualitative urine protein ≤ 1+; if qualitative urine protein is ≥ 2+, a 24-hour urine protein quantification test must be performed; if the 24-hour urine protein quantification is \< 1 g, it is acceptable; Coagulation function: (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 2 times the upper limit of normal (ULN).

Exclusion criteria

Exclusion Criteria:

1.A confirmed history of other types of cancer unrelated to the target cancer in this study (head and neck squamous cell carcinoma); 2.Subjects with central nervous system or ; 3.Patients with acute or chronic active or C; those with hepatitis B virus (HBV) DNA > 1,000 IU/mL who have failed antiviral therapy; those with virus (HCV) RNA > 10³ copies/mL who have been assessed as unsuitable for immunotherapy; and those who are simultaneously positive for hepatitis B surface antigen (HBsAg) and anti-HCV antibodies; 4.Any life-threatening bleeding episode within the past 3 months, including those requiring blood transfusion, surgery, or local treatment, or ongoing medication; 5.A history of arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or , pulmonary embolism, deep vein thrombosis, or any other serious thromboembolic event. Implantable venous access ports or catheter-related thrombosis, or superficial vein thrombosis, unless the thrombus is stable following conventional anticoagulation therapy. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg/day) is permitted; 6.Use of aspirin (> 325 mg/day) or other drugs known to inhibit function, such as dipyridamole or clopidogrel, for 10 consecutive days within 2 weeks prior to the first dose; 7.Symptomatic congestive heart failure ( Class II-IV). Symptomatic or poorly controlled arrhythmias. History of congenital long syndrome or a corrected QTc > 500 ms on screening (calculated using the Fridericia formula); 8.A severe bleeding tendency or coagulation disorder, or currently undergoing thrombolytic therapy; 9.A history of gastrointestinal perforation and/or fistula within the past 6 months; a history of intestinal obstruction (including partial intestinal obstruction requiring parenteral nutrition); extensive intestinal resection (partial colectomy or extensive small bowel resection complicated by chronic diarrhea); Crohn's disease; ulcerative colitis; or long-term chronic diarrhea; 10.A history of or current pulmonary conditions such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, or severe impairment of lung function; 11.Known history of alcohol abuse, psychotropic substance abuse, or drug use; 12.A history of specific neurological or psychiatric disorders, such as epilepsy, dementia, schizophrenia, etc; 13.Active pulmonary tuberculosis (TB), individuals currently undergoing antituberculosis treatment, or those who received antituberculosis treatment within one year prior to the first dose; 14.Individuals infected with (HIV) (HIV-1/2 antibody-positive) and individuals with known syphilis; 15.Active severe infections or infections that are not well clinically controlled. Severe infections within 4 weeks prior to the first dose, including but not limited to hospitalization due to complications from infection, bacteremia, or severe pneumonia; 16.Active disease requiring systemic treatment (e.g., disease-modifying antirheumatic drugs, , or ) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) is permitted. Known history of primary immunodeficiency. Patients who are only positive for autoimmune antibodies must be evaluated by the investigator to determine whether an autoimmune disease is present; 17.Use of immunosuppressive drugs within 4 weeks prior to the first dose, excluding topical corticosteroids administered via nasal spray, inhalation, or other routes, or systemic corticosteroids at physiological doses (i.e., no more than 10 mg/day of prednisone or an equivalent dose of other corticosteroids); temporary use of corticosteroids to treat dyspnea associated with conditions such as asthma or is permitted; 18.Within 4 weeks prior to the first dose, or if the patient is scheduled to receive an attenuated during the study; 19.Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or unhealed wounds, ulcers, or fractures. Tissue or other minor surgical procedures within 7 days prior to the first dose, excluding venipuncture or catheter placement for the purpose of intravenous infusion; 20.Uncontrolled or uncorrectable metabolic disorders, other non-malignant organ diseases, systemic diseases, or secondary reactions to cancer, which may result in a higher medical risk and/or uncertainty regarding survival prognosis; 21.A diagnosis of another within 5 years prior to the first dose, excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has been curatively resected. If another malignancy or hepatocellular carcinoma was diagnosed more than 5 years prior to dosing, a pathological or cytological diagnosis of the recurrent or metastatic lesions is required; 22.A history of severe allergic reactions to study drug components (such as the epa-loritovireli combination antibody, platinum agents, docetaxel, or paclitaxel); 23.Has received treatment in another clinical trial or is currently participating in another clinical study within 4 weeks prior to the first dose; 24.Pregnant or breastfeeding patients; 25.Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory test results that may lead to the following: increased risks associated with study participation or administration of the study drug, or interference with the interpretation of study results; and, in the investigator's judgment, render the patient ineligible for participation in this study.

.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Other
    single-arm

    The study includes a safety run-in phase (approximately 3 patients, with possible expansion to 6 if a dose-limiting toxicity is observed). Thereafter, patients are assigned to either combination antibody monotherapy or combination antibody plus chemotherapy based on PD-L1 combined positive score (CPS), symptom burden, disease characteristics, and patient preference.

    Drug: Iparomlimab and tuvonralimab

Interventions

  • DrugIparomlimab and tuvonralimab

    Drug pages: IparomlimabStudies of IparomlimabIparomlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TuvonralimabStudies of TuvonralimabTuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are assigned to either combination antibody monotherapy or combination antibody plus chemotherapy based on PD-L1 CPS, symptom burden, disease characteristics, and patient preference. Monotherapy arm: Iparomlimab and tuvonralimab combination antibody 5 mg/kg intravenously on day 1 of each 21-day cycle, repeated until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria. Combination arm: The same antibody regimen (5 mg/kg on day 1, every 3 weeks) plus chemotherapy for up to 6 cycles. Chemotherapy consists of: Platinum (carboplatin AUC 5 or cisplatin 75 mg/m²) on day 1, and Either docetaxel 75 mg/m² or paclitaxel 135-175 mg/m² on day 1. After completion of 6 chemotherapy cycles, patients continue on antibody monotherapy alone (same dose and schedule) as maintenance until disease progression or other discontinuation criteria.

    Also known as: with or without 6 cycles of platinum (carboplatin AUC 5 or cisplatin 75 mg/m²) plus docetaxel (75 mg/m²) or paclitaxel (135-175 mg/m²)

06

What researchers measure

Primary outcomes

  1. ORR

    The proportion of subjects achieving complete remission (CR) and partial remission (PR) out of the total number of subjects

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause

Secondary outcomes

  1. Disease control rate(DCR)

    The proportion of patients who achieved a response (partial response \[PR\] or complete response \[CR\]) or stable disease (SD) following treatment and were able to maintain this status for at least the minimum duration required, as defined by established response evaluation criteria (such as RECIST 1.1 for solid tumors).

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause

  2. 6-month progression-free survival rate

    The proportion of subjects who remained free of radiologically confirmed disease progression or death (whichever occurs first) from enrollment through 6 months

    Time frame: enrollment through 6 months

  3. 6-month overall survival rate

    The proportion of participants who were still alive at the end of the 6-month study period

    Time frame: enrollment through 6 months

  4. Incidence of adverse events

    Incidence, severity, and relationship to the study drug for all adverse events (AE), treatment-emergent adverse events (TEAE), serious adverse events (SAE), and immune-related adverse events (irAE)

    Time frame: through study completion,an average of 6 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 20 months is below that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 22, 2026
StartEst.
Apr 13, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546383
Lead sponsor
The Second Affiliated Hospital of Hainan Medical University
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 13, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

yuecan zeng, doctor
Contact
wellyy2005@hainmc.edu.cn
19946610752
junnv xu
Contact
xujunnv@sina.com
18208946196

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iparomlimab · Tuvonralimab

Start the discussion